The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Rosell, R. [1 ,2 ]
Jain, A. [3 ]
Codony-Servat, J. [4 ]
Shivamallu, C. [3 ]
Kollur, S. Prasad [5 ]
Prasad, A. [3 ]
Jantus-Lewintre, E. [6 ]
Ito, M. [7 ]
Cardona, A. F. [8 ]
Arrieta, O. [9 ]
Cao, P. [10 ]
Cai, X. [10 ]
Xing, B. [10 ]
Pedraz-Valdunciel, C. [11 ]
Dantes, Z. [12 ]
Sullivan, I. [2 ]
Aguilar, A. [2 ]
Molina-Vila, M. A.
Gonzalez-Cao, M. [2 ]
机构：
[1] Inst Germans Trias i Pujol, Badalona, Spain
[2] Inst Oncol Dr Rosell IOR, Quiron Dexeus Univ Inst, Barcelona, Spain
[3] JSS Acad Higher Educ & Res Mysuru, Mysuru, Karnataka, India
[4] Quiron Dexeus Univ Inst, Pangaea Oncol, Barcelona, Spain
[5] Amrita Vishwa Vidyapeetham, Mysuru, Karnataka, India
[6] Fdn Invest Hosp Gen Univ Valencia, Valencia, Spain
[7] Hiroshima Univ, Inst Biomed Hlth Sci, Hiroshima, Japan
[8] FICMAC Invest Clin Mol Canc, Bogota, Colombia
[9] Inst Nacl Cancerol INCan, Mexico City, DF, Mexico
[10] Nanjing Univ Chinese Med, Nanjing, Peoples R China
[11] Invitrocue Iberia, Barcelona, Spain
[12] Invitrocue Europe AG, Munich, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
MET inhibitor; KRASG12C; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA04.09
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [1] Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. P.
    Prasad, A.
    Vishwanath, P.
    Jantus Lewintre, E.
    Ito, M.
    Cardona Zorrilla, A. F.
    Arrieta Rodriguez, O. G.
    Pedraz-Valdunciel, C.
    Gonzalez Nieto, J.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez Cao, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1188 - S1188
  • [2] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [3] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Alessandro Di Federico
    Ilaria Ricciotti
    Valentina Favorito
    Sandra Vietti Michelina
    Pietro Scaparone
    Giulio Metro
    Andrea De Giglio
    Federica Pecci
    Giuseppe Lamberti
    Chiara Ambrogio
    Biagio Ricciuti
    Current Oncology Reports, 2023, 25 : 1017 - 1029
  • [4] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Di Federico, Alessandro
    Ricciotti, Ilaria
    Favorito, Valentina
    Michelina, Sandra Vietti
    Scaparone, Pietro
    Metro, Giulio
    De Giglio, Andrea
    Pecci, Federica
    Lamberti, Giuseppe
    Ambrogio, Chiara
    Ricciuti, Biagio
    CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 1017 - 1029
  • [5] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [6] Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
    Zheng, Xinting
    Luo, Jiamin
    Liu, Wei
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    Lin, Lizhu
    DRUGS OF TODAY, 2022, 58 (04) : 175 - 185
  • [7] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
    Pinto, L. Masfarre
    Parreira, A. S. D. F. M.
    Unanua, N. Castro
    Rocha, P.
    Ruiz, I. Morilla
    Sanchez, L. Teijeira
    Clave, S.
    Gorro, N. Navarro
    Mora, R. Bach
    Sanchez, I.
    Campos, M. A. Galindo
    Garcia, A. Taus
    Martinez, A. Azkarate
    Fabregat, R. Marse
    Paricio, B. Bellosillo
    Arasanz, H.
    Aguillo, M. Martinez
    Arriola, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [8] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [9] Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
    Wu, Markus Y.
    Zhang, Eric W.
    Strickland, Matthew R.
    Mendoza, Dexter P.
    Lipkin, Lev
    Lennerz, Jochen K.
    Gainor, Justin F.
    Heist, Rebecca S.
    Digumarthy, Subba R.
    CANCERS, 2021, 13 (14)
  • [10] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
    Tereza Vaclova
    Atanu Chakraborty
    James Sherwood
    Sarah Ross
    Danielle Carroll
    J. Carl Barrett
    Julian Downward
    Elza C. de Bruin
    Scientific Reports, 12
12345